Table 3.

Predictors of switch to BOT: Univariate and multivariate (pooled) HRs and corresponding lower and upper bounds of the 95 % CIs

	Endpoint
	BOT	OAD-End
	(N = 6,705)	(N = 10,547)
Univariate
Age	1.000 (0.998,1.002)	1.002 (1.001,1.004)
BMI	1.016 (1.012,1.020)	1.006 (1.004,1.010)
Diabetes duration	1.044 (1.041,1.047)	1.003 (0.999,1.007)
HbA1c	1.264 (1.245,1.284)	1.003 (0.984,1.022)
FPG	1.127 (1.109,1.046)	1.011 (0.999,1.023)
Gender	0.934 (0.891,0.981)	1.001 (0.963,1.040)
Microvascular diseasesa	1.226 (1.168,1.287)	0.974 (0.936,1.014)
Macrovascular diseasesa	1.115 (1.056,1.178)	1.131 (1.083,1.182)
Hypoglycaemiaa	2.567 (1.850,3.563)	1.007 (0.634,1.599)
No. OADs at baseline 2 vs. 1	1.288 (1.206,1.376)	0.679 (0.636,0.725)
No. OADs at baseline 3 vs. 1	1.295 (1.054,1.592)	0.605 (0.483,0.758)
Concomitant Medication yes vs. no	1.144 (1.090,1.200)	0.834 (0.802,0.866)
Multivariate
Age	0.993 (0.991,0.996)	1.003 (1.001,1.005)
BMI	1.012 (1.007,1.017)	1.009 (1.005,1.012)
Diabetes duration	1.046 (1.043,1.049)	1.003 (0.999,1.007)
HbA1c	1.227 (1.197,1.257)	0.999 (0.970,1.029)
FPG	1.022 (0.999,1.046)	1.014 (0.997,1.033)
Gender	0.950 (0.903,0.998)	0.995 (0.956,1.035)
Microvascular diseasesa	1.141 (1.082,1.203)	0.947 (0.908,0.988)
Macrovascular diseasesa	1.065 (1.004,1.130)	1.152 (1.100,1.208)
Hypoglycaemiaa	1.708 (1.208,2.415)	0.956 (0.601,1.520)
No. OADs at baseline 2 vs. 1	1.121 (1.047,1.199)	0.680 (0.636,0.727)
No. OADs at baseline 3 vs. 1	0.981 (0.796,1.210)	0.604 (0.482,0.758)
Concomitant Medication yes vs. no	1.094 (1.042,1.149)	0.824 (0.793,0.857)

Legend: BOT basal supported oral therapy, BMI body mass index, HbA1c glycated haemoglobin, FPG fasting plasma glucose, OAD oral antidiabetic drug, HR hazard ratio. Multivariate adjustment includes all factors given in the table

^aPatient and/or physician reported